Pranlukast
From Wikipedia, the free encyclopedia
Pranlukast
|
|
Systematic (IUPAC) name | |
N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-7-yl]- 4-(4-phenylbutoxy)benzamide |
|
Identifiers | |
CAS number | ? |
ATC code | R03DC02 |
PubChem | 115100 |
Chemical data | |
Formula | C27H23N5O4 |
Mol. weight | 481.503 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic (mainly CYP3A4)[1] |
Half life | 1.5 hours[1] |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Oral |
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast).
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.
[edit] References
- ^ a b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma.". Drug Metab Pharmacokinet 21 (2): 133-9. PMID 16702733.
Medications commonly used in asthma and COPD (primarily R03) edit | ||
---|---|---|
Anticholinergics: | ||
Short acting β2-agonists: | ||
Long acting β2-agonists (LABA): | Clenbuterol, Formoterol, Salmeterol | |
Corticosteroids: | ||
Leukotriene antagonists: |
Montelukast, Pranlukast, Zafirlukast |
|
Xanthines: | ||
Mast cell stabilizers: | ||
Combination products: |
Budesonide/formoterol, Fluticasone/salmeterol, Ipratropium/salbutamol |